Eli Lilly’s obesity drug Zepbound is now covered by Medicare for sleep apnea treatment, expanding access to the costly ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP breathing machines, surgery, a dental mouthpiece and even an implantable pac ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

CHICAGO As 2025 begins and millions of Americans start working to keep their New Year’s resolutions, Attorney General Kwame ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...